Basecamp Research announced a $140 million Series C financing to train a new generation of EDEN models and advance a pipeline of AI-designed therapeutics towards clinical development.
Basecamp's ambition is to develop cures for diseases that remain incurable by designing medicines that reprogram the body to repair itself. The company combines frontier AI models trained on proprietary biological data with technology for writing DNA sequences into cells.
Basecamp is applying EDEN, its biological foundation model, to in vivo cell therapy. By pairing EDEN's ability to design long and complex DNA sequences with large serine recombinases that can precisely integrate them into the genome, Basecamp's platform aims to make cell therapies more sophisticated, more customizable and simpler to administer.
The oversubscribed round was led by S32, with participation from Anthropic's Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!